Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT

A prospective cohort study by the Kanto Study Group for Cell Therapy

M. Tanaka, H. Kanamori, K. Matsumoto, T. Tachibana, A. Numata, K. Ohashi, T. Kobayashi, C. Nakaseko, Y. Kanda, E. Yamazaki, S. Fujisawa, J. Ooi, T. Sakura, N. Aotsuka, M. Onoda, S. Machida, Jun Kato, K. Usuki, R. Watanabe, J. Taguchi & 5 others S. Yano, T. Saito, S. Takahashi, H. Sakamaki, Shinichiro Okamoto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This prospective study aimed to investigate the influence of pretransplant serum ferritin levels on the outcomes of allogeneic hematopoietic SCT (HSCT). In total, 190 patients with acute leukemia or myelodysplastic syndrome were consecutively enrolled. The patients were divided into two groups: low-ferritin group (<1000 ng/mL) and high-ferritin group (≥1000 ng/mL). The primary end point was the cumulative incidence of infection within 100 days after HSCT, which was similar between the two groups: bloodstream infection, 35 vs 38%, P=0.65; bacterial infection, 44 vs 41%, P=0.68; and fungal infection, 6 vs 8%, P=0.71. The 1-year adjusted probability of OS of the high-ferritin group was significantly lower than that of the low-ferritin group (76 vs 63%, P=0.017). Using receiver operating characteristic curve, the threshold of pretransplant serum ferritin levels for bloodstream infection was 1400 ng/mL; the threshold for OS, EFS and non-relapse mortality was 1349 ng/mL. In conclusion, pretransplant serum ferritin levels of ≥1000 ng/mL did not influence the incidence of infection but adversely affected OS after HSCT. A higher threshold of pretransplant serum ferritin levels may predict HSCT outcomes.

Original languageEnglish
Pages (from-to)727-733
Number of pages7
JournalBone Marrow Transplantation
Volume50
Issue number5
DOIs
Publication statusPublished - 2015 May 8

Fingerprint

Ferritins
Group Psychotherapy
Cell- and Tissue-Based Therapy
Cohort Studies
Prospective Studies
Serum
Infection
Mycoses
Myelodysplastic Syndromes
Incidence
Bacterial Infections
ROC Curve
Leukemia
Mortality

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT : A prospective cohort study by the Kanto Study Group for Cell Therapy. / Tanaka, M.; Kanamori, H.; Matsumoto, K.; Tachibana, T.; Numata, A.; Ohashi, K.; Kobayashi, T.; Nakaseko, C.; Kanda, Y.; Yamazaki, E.; Fujisawa, S.; Ooi, J.; Sakura, T.; Aotsuka, N.; Onoda, M.; Machida, S.; Kato, Jun; Usuki, K.; Watanabe, R.; Taguchi, J.; Yano, S.; Saito, T.; Takahashi, S.; Sakamaki, H.; Okamoto, Shinichiro.

In: Bone Marrow Transplantation, Vol. 50, No. 5, 08.05.2015, p. 727-733.

Research output: Contribution to journalArticle

Tanaka, M, Kanamori, H, Matsumoto, K, Tachibana, T, Numata, A, Ohashi, K, Kobayashi, T, Nakaseko, C, Kanda, Y, Yamazaki, E, Fujisawa, S, Ooi, J, Sakura, T, Aotsuka, N, Onoda, M, Machida, S, Kato, J, Usuki, K, Watanabe, R, Taguchi, J, Yano, S, Saito, T, Takahashi, S, Sakamaki, H & Okamoto, S 2015, 'Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: A prospective cohort study by the Kanto Study Group for Cell Therapy', Bone Marrow Transplantation, vol. 50, no. 5, pp. 727-733. https://doi.org/10.1038/bmt.2015.17
Tanaka, M. ; Kanamori, H. ; Matsumoto, K. ; Tachibana, T. ; Numata, A. ; Ohashi, K. ; Kobayashi, T. ; Nakaseko, C. ; Kanda, Y. ; Yamazaki, E. ; Fujisawa, S. ; Ooi, J. ; Sakura, T. ; Aotsuka, N. ; Onoda, M. ; Machida, S. ; Kato, Jun ; Usuki, K. ; Watanabe, R. ; Taguchi, J. ; Yano, S. ; Saito, T. ; Takahashi, S. ; Sakamaki, H. ; Okamoto, Shinichiro. / Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT : A prospective cohort study by the Kanto Study Group for Cell Therapy. In: Bone Marrow Transplantation. 2015 ; Vol. 50, No. 5. pp. 727-733.
@article{261f26902d574b18980de758d6f813e4,
title = "Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: A prospective cohort study by the Kanto Study Group for Cell Therapy",
abstract = "This prospective study aimed to investigate the influence of pretransplant serum ferritin levels on the outcomes of allogeneic hematopoietic SCT (HSCT). In total, 190 patients with acute leukemia or myelodysplastic syndrome were consecutively enrolled. The patients were divided into two groups: low-ferritin group (<1000 ng/mL) and high-ferritin group (≥1000 ng/mL). The primary end point was the cumulative incidence of infection within 100 days after HSCT, which was similar between the two groups: bloodstream infection, 35 vs 38{\%}, P=0.65; bacterial infection, 44 vs 41{\%}, P=0.68; and fungal infection, 6 vs 8{\%}, P=0.71. The 1-year adjusted probability of OS of the high-ferritin group was significantly lower than that of the low-ferritin group (76 vs 63{\%}, P=0.017). Using receiver operating characteristic curve, the threshold of pretransplant serum ferritin levels for bloodstream infection was 1400 ng/mL; the threshold for OS, EFS and non-relapse mortality was 1349 ng/mL. In conclusion, pretransplant serum ferritin levels of ≥1000 ng/mL did not influence the incidence of infection but adversely affected OS after HSCT. A higher threshold of pretransplant serum ferritin levels may predict HSCT outcomes.",
author = "M. Tanaka and H. Kanamori and K. Matsumoto and T. Tachibana and A. Numata and K. Ohashi and T. Kobayashi and C. Nakaseko and Y. Kanda and E. Yamazaki and S. Fujisawa and J. Ooi and T. Sakura and N. Aotsuka and M. Onoda and S. Machida and Jun Kato and K. Usuki and R. Watanabe and J. Taguchi and S. Yano and T. Saito and S. Takahashi and H. Sakamaki and Shinichiro Okamoto",
year = "2015",
month = "5",
day = "8",
doi = "10.1038/bmt.2015.17",
language = "English",
volume = "50",
pages = "727--733",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT

T2 - A prospective cohort study by the Kanto Study Group for Cell Therapy

AU - Tanaka, M.

AU - Kanamori, H.

AU - Matsumoto, K.

AU - Tachibana, T.

AU - Numata, A.

AU - Ohashi, K.

AU - Kobayashi, T.

AU - Nakaseko, C.

AU - Kanda, Y.

AU - Yamazaki, E.

AU - Fujisawa, S.

AU - Ooi, J.

AU - Sakura, T.

AU - Aotsuka, N.

AU - Onoda, M.

AU - Machida, S.

AU - Kato, Jun

AU - Usuki, K.

AU - Watanabe, R.

AU - Taguchi, J.

AU - Yano, S.

AU - Saito, T.

AU - Takahashi, S.

AU - Sakamaki, H.

AU - Okamoto, Shinichiro

PY - 2015/5/8

Y1 - 2015/5/8

N2 - This prospective study aimed to investigate the influence of pretransplant serum ferritin levels on the outcomes of allogeneic hematopoietic SCT (HSCT). In total, 190 patients with acute leukemia or myelodysplastic syndrome were consecutively enrolled. The patients were divided into two groups: low-ferritin group (<1000 ng/mL) and high-ferritin group (≥1000 ng/mL). The primary end point was the cumulative incidence of infection within 100 days after HSCT, which was similar between the two groups: bloodstream infection, 35 vs 38%, P=0.65; bacterial infection, 44 vs 41%, P=0.68; and fungal infection, 6 vs 8%, P=0.71. The 1-year adjusted probability of OS of the high-ferritin group was significantly lower than that of the low-ferritin group (76 vs 63%, P=0.017). Using receiver operating characteristic curve, the threshold of pretransplant serum ferritin levels for bloodstream infection was 1400 ng/mL; the threshold for OS, EFS and non-relapse mortality was 1349 ng/mL. In conclusion, pretransplant serum ferritin levels of ≥1000 ng/mL did not influence the incidence of infection but adversely affected OS after HSCT. A higher threshold of pretransplant serum ferritin levels may predict HSCT outcomes.

AB - This prospective study aimed to investigate the influence of pretransplant serum ferritin levels on the outcomes of allogeneic hematopoietic SCT (HSCT). In total, 190 patients with acute leukemia or myelodysplastic syndrome were consecutively enrolled. The patients were divided into two groups: low-ferritin group (<1000 ng/mL) and high-ferritin group (≥1000 ng/mL). The primary end point was the cumulative incidence of infection within 100 days after HSCT, which was similar between the two groups: bloodstream infection, 35 vs 38%, P=0.65; bacterial infection, 44 vs 41%, P=0.68; and fungal infection, 6 vs 8%, P=0.71. The 1-year adjusted probability of OS of the high-ferritin group was significantly lower than that of the low-ferritin group (76 vs 63%, P=0.017). Using receiver operating characteristic curve, the threshold of pretransplant serum ferritin levels for bloodstream infection was 1400 ng/mL; the threshold for OS, EFS and non-relapse mortality was 1349 ng/mL. In conclusion, pretransplant serum ferritin levels of ≥1000 ng/mL did not influence the incidence of infection but adversely affected OS after HSCT. A higher threshold of pretransplant serum ferritin levels may predict HSCT outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84928924283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928924283&partnerID=8YFLogxK

U2 - 10.1038/bmt.2015.17

DO - 10.1038/bmt.2015.17

M3 - Article

VL - 50

SP - 727

EP - 733

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -